Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 15/20 | 0.96 |
| ▸ | RXRA | P19793 | 2/20 | 0.84 |
| ▸ | RARG | P13631 | 1/20 | 0.84 |
| ▸ | PPARA | Q07869 | 2/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL3379949 | 1.00 | PPARG (0.96) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3379945 | 1.00 | PPARG (0.96) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5574033 | 1.00 | PPARG (0.96) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3377103 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3375739 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL1489117 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL6830507 | 0.98 | PPARG (0.96) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5169 | 0.98 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL7052472 | 0.98 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL29530259 | 0.98 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078885-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| US-20140248357-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8815837-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| EP-2222272-B1 | Respiratory disease treatment | PULMAGEN THERAPEUTICS INFLAMMATION LTD (GB) | 2012-11-07 | — | — | EP | disclosed |
| US-20120264787-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-10-18 | — | — | US | disclosed |
| US-8236786-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264787-A1 | Respiratory Disease Treatment | IL5, PPARD, PPARG | PPARG 3/4885RXRA 191/4885RARG 90/4885 |
| US-20140248357-A1 | Respiratory Disease Treatment | IL5, PPARD, SLC5A1 | PPARG 4/4885RXRA 272/4885RARG 271/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | PPARG 3/4885RXRA 191/4885RARG 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.